Tesamorelin
A synthetic growth-hormone-releasing-hormone (GHRH) analog. Studied in research models for GH-axis signaling. Clinically approved as a drug — research-grade for in-vitro use only.
Ordered by current research-market traction. Each entry describes what the published literature studies — not what anyone should take.
A synthetic growth-hormone-releasing-hormone (GHRH) analog. Studied in research models for GH-axis signaling. Clinically approved as a drug — research-grade for in-vitro use only.
Dual GIP/GLP-1 receptor agonist; studied in incretin-signaling research models. Clinically approved — research-grade for in-vitro reference only.
A 15-amino-acid synthetic peptide derived from a gastric protein. Studied in animal models for angiogenesis and connective-tissue repair pathways.
Biohacker forums commonly discuss it during recovery from soft-tissue or joint strain — anecdotal user reports, not clinical evidence.
A synthetic fragment of thymosin beta-4. Studied for actin regulation, cell migration, and tissue organization.
Often paired with BPC-157 in community recovery protocols for soft-tissue and tendon work — anecdotal, not verified.
Triple GIP/GLP-1/glucagon receptor agonist under clinical development; widely indexed in current metabolic-research literature.
A growth-hormone-releasing-hormone (GHRH) analog. Studied in research models for GH-axis signaling.
Community users discuss it in the context of sleep quality, recovery, and body composition — anecdotal, not clinical.
A selective ghrelin-receptor agonist (GHRP). Frequently referenced alongside CJC-1295 in GH-secretagogue research.
Frequently stacked with CJC-1295 in community protocols targeting the same outcomes — anecdotal, not endorsed.
A copper-binding tripeptide. Studied for collagen synthesis, extracellular-matrix remodeling, and wound-healing pathways in research models.
Widely discussed in skin-care, hair, and topical-formulation communities — anecdotal user reports, not clinical evidence.
A mitochondrial-derived peptide. Studied in research models for metabolic regulation and exercise-mimetic pathways.
Discussed in metabolic-health and longevity communities — user accounts anecdotal, not clinical.
A long-acting amylin receptor agonist under clinical development; widely indexed in current satiety and metabolic-research literature. Often referenced alongside Semaglutide in the CagriSema combination under trial.
All peptides listed on this page are for research use only. They are not approved for human or animal consumption. Nothing on this page is medical advice, and Peptide Rhino does not endorse, recommend, or facilitate human use.
Community-Reports sections reflect anecdotal user accounts from public forums. They are not verified by Peptide Rhino, not endorsed, and not medical advice. Where peptides are clinically approved drugs (Tesamorelin, Tirzepatide) or clinical-development drugs (Retatrutide, Cagrilintide), this page deliberately omits anecdotal reporting to comply with applicable regulations.